Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus standard of care in untreated systemic lupus erythematosus
ChiCTR2100043138Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guilin Medical University
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by The First Affiliated Hospital of Guilin Medical University. Primary endpoints: SELENA-SLEDAI and BILAG. Started Apr 2021; status: recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2100043138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043138.